Regeneron’s Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

All NewsOctober 28, 2025

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent